Pooled analysis of three pharmacokinetic studies comparing biosimilar MB02 and reference bevacizumab

AIM: The aim of this study was to add robustness and provide further evidence on the bioequivalence, safety and immunogenicity between MB02 and reference bevacizumab. No similar study has been performed before with a biosimilar monoclonal antibody. METHODS: Population analysis by pooling data from t...

Descripción completa

Detalles Bibliográficos
Autores principales: Miguel‐Lillo, B., Sánchez‐Vidaurre, Sara, Pérez Díaz, L., Paravisini, A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10622740/
https://www.ncbi.nlm.nih.gov/pubmed/37920875
http://dx.doi.org/10.1002/prp2.1139

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10622740/
https://www.ncbi.nlm.nih.gov/pubmed/37920875
http://dx.doi.org/10.1002/prp2.1139

Ejemplares similares